Skip to main content
Premium Trial:

Request an Annual Quote

Tripos Shares Lose Ground Gained on Pfizer Extension

NEW YORK, Nov. 18 (GenomeWeb News) - Shares in Tripos lost almost all the ground they gained since Monday, when the company said it had extended a multimillion-dollar software license agreement with Pfizer.


Shares in the St. Louis bioinformatics company were down 9.23 percent at $4.92 in mid-afternoon trading after starting the day at $.5.36. On Monday, the stock climbed 15 percent to close at $5.25 after the Pfizer news jolted investors. The shares closed at $4.80 the day before the announcement.


The two companies initially announced a wide area network partnership in January 2001 that Pfizer employ a "broad array" of Tripos' drug-discovery software tools, including the SYBYL and UNITY programs.

Details of the extended agreement were not disclosed.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.